Actinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH

Stock Information for Actinium Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Actinium Pharmaceuticals Inc.

ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for Investors - Contact Levi & Korsinsky
Faruqi & Faruqi Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 26, 2025 - ATNM
Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ATNM
ATNM INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In ATNM To Contact Him Directly To Discuss Their Options

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.